{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:25:12Z","timestamp":1781555112180,"version":"3.54.5"},"reference-count":83,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare B-cell malignancy that remains challenging to treat with high rates of relapse. Frontline strategies range from intensive chemotherapy followed by consolidation with autologous stem cell transplant (ASCT), to less-intensive therapies including combination regimens. The treatment landscape for relapsed patients includes Bruton tyrosine kinase (BTK) inhibitors among other targeted treatments. Novel agents such as the selective BCL2 inhibitor venetoclax showed high response rates when used as monotherapy for refractory relapsed MCL. The rituximab, bendamustine, and cytarabine (R-BAC) regimen, while response rates were high, were not durable. Chimeric antigen receptor (CAR) T-cell products targeting CD19 have been efficacious in relapsed and refractory MCL patients. Brexucabtagene autoleucel (brexu-cel, formerly KTE-X19) was approved by US Food and Drug Administration (FDA) in July, 2020, for treatment of refractory and relapsed MCL. This article provides an overview for the available management strategies for relapsed MCL and examines the role of CAR T-cell in the current and future treatment of MCL.<\/jats:p>","DOI":"10.1177\/20406207221080738","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T04:31:40Z","timestamp":1645849900000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-9396","authenticated-orcid":false,"given":"Bushra","family":"Tbakhi","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,26]]},"reference":[{"key":"bibr1-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-189977"},{"key":"bibr2-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14699"},{"key":"bibr3-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2067"},{"key":"bibr4-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"bibr5-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"bibr6-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"bibr7-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1002\/hon.146_2630"},{"key":"bibr8-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"bibr9-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"bibr10-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2565"},{"key":"bibr11-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1002\/hon.15_2629"},{"key":"bibr12-20406207221080738","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"bibr13-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr14-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"bibr15-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"bibr16-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"bibr17-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"bibr18-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.880.880"},{"key":"bibr19-20406207221080738","volume-title":"Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)","author":"Hermine O","year":"2012"},{"key":"bibr20-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"bibr21-20406207221080738","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine O","year":"2016","journal-title":"Lancet"},{"key":"bibr22-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001355"},{"key":"bibr23-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"bibr24-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"bibr25-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"bibr26-20406207221080738","volume-title":"Bendamustine plus rituximab (BR) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL)\u20137 year updated results from the StiL NHL1 study","author":"Rummel MJ","year":"2014"},{"key":"bibr27-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"bibr28-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2762"},{"key":"bibr29-20406207221080738","first-page":"154","volume":"130","author":"Ruan J","year":"2017","journal-title":"Blood"},{"key":"bibr30-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"bibr31-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"bibr32-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"bibr33-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1615"},{"key":"bibr34-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114528"},{"key":"bibr35-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"bibr36-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"bibr37-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"bibr38-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70062-6"},{"key":"bibr39-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.10.1735"},{"key":"bibr40-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.168"},{"key":"bibr41-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4281"},{"key":"bibr42-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"bibr43-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"bibr44-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"bibr45-20406207221080738","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220590"},{"key":"bibr46-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110327"},{"key":"bibr47-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"bibr48-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"bibr49-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"bibr50-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0023-2"},{"key":"bibr51-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16416"},{"key":"bibr52-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"bibr53-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1457148"},{"key":"bibr54-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1283032"},{"key":"bibr55-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560284"},{"key":"bibr56-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"bibr57-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0067-3"},{"key":"bibr58-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2087-z"},{"key":"bibr59-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15723"},{"key":"bibr60-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"bibr61-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"bibr62-20406207221080738","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S163225"},{"key":"bibr63-20406207221080738","first-page":"577","volume":"130","author":"Schuster SJ","year":"2017","journal-title":"Blood"},{"key":"bibr64-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127508"},{"key":"bibr65-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr66-20406207221080738","unstructured":"Health UDo and Services H. National Cancer Institute: Common terminology criteria for adverse events (Version 4.03), 2010, https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"bibr67-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr68-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"bibr69-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"bibr70-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100201.131730"},{"key":"bibr71-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"bibr72-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1227.1227"},{"key":"bibr73-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13239"},{"key":"bibr74-20406207221080738","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S145039"},{"key":"bibr75-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139063"},{"key":"bibr76-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3023"},{"key":"bibr77-20406207221080738","unstructured":"Program NCICTE. Common terminology criteria for adverse events (CTCAE). Cancer therapy evaluation program, 2003, https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"bibr78-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127150"},{"key":"bibr79-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.247"},{"key":"bibr80-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136158"},{"key":"bibr81-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13983"},{"key":"bibr82-20406207221080738","volume-title":"Safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study","author":"Song Y","year":"2019"},{"key":"bibr83-20406207221080738","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1527"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221080738","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207221080738","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221080738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:15:54Z","timestamp":1777590954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207221080738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":83,"alternative-id":["10.1177\/20406207221080738"],"URL":"https:\/\/doi.org\/10.1177\/20406207221080738","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"20406207221080738"}}